{"id":"W2901635918","doi":"10.1016/j.cgh.2018.11.003","title":"Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study","year":2018,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Saskatchewan; University of Calgary; Mount Sinai Hospital; University of Toronto; Dalhousie University; University of British Columbia; Arthritis Research Centre of Canada; University of Ottawa; Institute for Clinical Evaluative Sciences; Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Manitoba","funders":"Crohn's and Colitis Canada; Takeda Pharmaceutical Company; AbbVie Canada; Shire; Janssen Canada; Merck Canada; Pfizer Canada; AbbVie","keywords":"Medicine; Internal medicine; Inflammatory bowel disease; Hazard ratio; Ulcerative colitis; Concomitant; Combination therapy; Tumor necrosis factor alpha; Proportional hazards model; Population; Crohn's disease; Adalimumab; Cohort; Gastroenterology; Disease; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003538116,0.000448306,0.0009001271,0.0004245138,0.0003699233,0.0007231599,0.0003336765,0.0005588082,0.001570045],"category_scores_gemma":[0.001239069,0.0003081935,0.001304779,0.0008905343,0.0001736746,0.000453252,0.0002648172,0.001037938,0.0001663434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00026188,"about_ca_system_score_gemma":0.0002635251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285592,"about_ca_topic_score_gemma":0.002449267,"domain_scores_codex":[0.9995906,0.0001241952,0.00003717024,0.0001277177,0.00005678876,0.00006354759],"domain_scores_gemma":[0.9991056,0.0001851897,0.0004087139,0.00008575486,0.00003795389,0.0001766621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02626167,0.0007943055,0.9529331,0.0001150231,0.002805614,0.0003209668,0.00007986638,0.0001457685,0.004234468,0.00007182812,0.0004500136,0.0117875],"study_design_scores_gemma":[0.0007903652,0.003251302,0.9916778,0.00002651169,0.002423775,0.000472878,0.0001153927,0.0004329555,0.0002968861,0.000106261,0.000388276,0.00001768668],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978737,0.001438093,0.00005538879,0.00006590366,0.00002291013,0.000006350917,0.0001923455,0.000004163127,0.0003410594],"genre_scores_gemma":[0.9988654,0.0004618272,0.00009661447,0.00005874372,0.00004246898,0.000007941649,0.0002594776,0.000003138281,0.0002043435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001570045,"threshold_uncertainty_score":0.005252302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.014290108032312,"score_gpt":0.2809572157851705,"score_spread":0.2666671077528585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}